The Drugs Controller General of India (DCGI) has approved the market authorization of India’s first quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer. The Serum Institute of India (SII) will produce this vaccine. CEO of The Serum Institute of India Adar Poonawalla tweeted the information. For the first time, an inexpensive and widely available HPV vaccination made in India will be available to treat cervical cancer in female patients. Later this year, SII hopes to launch it, and we are grateful to the DCGI, MoHFW INDIA, for their approval.
Following an assessment of the clinical trial results for the vaccine, the National Technical Advisory Group on Immunization (NTAGI) recently gave its approval to the qHPV. The Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer, which was produced domestically by Serum Institute of India (SII), was recommended for standard market authorization on June 15. After the vaccine’s phase 3 data were deemed to be satisfactory, suggestions were made.
Important Takeaways For All Competitive Exams:
The Daily Current Affairs Quiz which keeps you updated with the current events happening all…
Traffic congestion is a serious problem in many Asian cities, affecting millions of people every…
Uttar Pradesh is a state rich in culture, history, and religious significance. Among its many…
Many countries around the world have unique nicknames that reflect their culture, history, or geography.…
The World Day of Remembrance for Road Traffic Victims (WDR) is observed on the third…
On the occasion of the inauguration of Symbiosis International University’s first international campus at Dubai…